We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIESSE DIAGNOSTICA SENESE SPA

DIESSE Diagnostica Senese S.P.A. manufactures in-vitro diagnostics systems for the hematology, seroimmunology and bac... read more Featured Products: More products

Download Mobile App





DIESSE Diagnostica Unveils CHORUS EVO Immunochemistry Analyzer

By LabMedica International staff writers
Posted on 25 May 2023
Print article
Image: The CHORUS EVO immunochemistry analyzer features innovative digital technologies (Photo courtesy of Diesse Diagnostica)
Image: The CHORUS EVO immunochemistry analyzer features innovative digital technologies (Photo courtesy of Diesse Diagnostica)

Diesse Diagnostica Senese S.p.A. (Rigoni, Italy) is unveiling its new innovative immunochemistry analyzer, the CHORUS EVO, at this year's WorldLab-EuroMedLab.

The cutting-edge DIESSE CHORUS line comprises a compact instrument and consumables for immunometric assays. Known for simplicity, high-quality mono-test results, and reliability, the CHORUS line is the perfect tool for conducting small-batch diagnostic tests. Its design ensures maximum flexibility in managing the workflow of a clinical laboratory. Even when lab automation isn't viable, the CHORUS line stands out as a go-to solution for immediate, simple, and accurate testing. Its mono-test format facilitates operational efficiency and minimal waste, which is a boon for smaller test volumes. This makes CHORUS an excellent resource for Physician Office Laboratories (POLs) and other diagnostic laboratories, providing them with analytical quality and operational efficiency.

In line with developing instruments featuring cutting-edge technology that meet Italian design and its vision of "Diagnostics Evolution", DIESSE has now unveiled the CHORUS EVO immunochemistry analyzer. CHORUS EVO is a new-generation analytical instrument that integrates innovative digital technology, paving the way for the integration of artificial intelligence functions. In order to achieve this, DIESSE is collaborating with the SAIHUB consortium, a network of companies that specialize in applying artificial intelligence in life sciences.

Their collaborative effort is directed towards creating a data platform, to which the instruments will be connected, facilitating a large-scale data accumulation. This setup will enable direct digital communication between the company and individual instruments, making it possible for the company to monitor the instruments through the data platform. Moreover, it will harness beneficial artificial intelligence functions to train the analyzers to enhance their performance and employ predictive diagnostics to preempt machine downtime. The project also plans to incorporate computer vision systems rooted in artificial intelligence to further optimize the diagnostic capabilities of the instruments.

Related Links:
Diesse Diagnostica Senese Spa

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
Rheumatoid Arthritis Test
Finecare RF Rapid Quantitative Test
New
Gastrointestinal Infection Test
RIDA QUICK Cryptosporidium/Giardia/Entamoeba Combi Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.